Year: 2015
Type: article
Abstract: New promising targets and targeted drugs for treatment of aggressive forms of systemic mastocytosis are few; in this issue of Blood, Blatt et al(1) provide evidence that aberrant Ki-1 antigen (CD30) expression on neoplastic mast cells may serve as a therapeutic target of brentuximab-vedotin alone or in combination with KIT-targeting drugs.
Source: Blood
Author: Irina Maric
Institution: National Institutes of Health
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2427976272